March 10, 2008 at 07:00 AM EDT
Antares Pharma to Report 2007 Results on March 26, 2008

Antares Pharma, Inc. (Amex:AIS) today announced that it will report 2007 results on Wednesday, March 26, 2008, before the open of the U.S. financial markets.

Jack E. Stover, President and Chief Executive Officer, and other members of Antares senior management will provide a company update and review 2007 results via webcast and conference call on Wednesday, March 26, 2008, at 8:00 a.m. ET. The webcast of this call will be available from the investors/media section of the Company's web site, www.antarespharma.com. Alternatively, callers may participate in the conference call by dialing 800.762.8779 (domestic) or 480.248.5081 (international). Participants should reference the Antares Pharma conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through April 9, 2008. To access the replay, callers should dial 800.406.7325 (domestic) or 303.590.3030 (international). The passcode is 3853688.

About Antares Pharma

Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated drug delivery platforms: the ATDTM Advanced Transdermal Delivery system, subcutaneous injection technology platforms including both VibexTM disposable mini-needle injection device and ValeoTM/Vision® reusable needle-free injection devices; and Easy TecTM oral fast-melt technology. Two of the platforms have generated FDA approved products. Antares Pharma leverages its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. The Companys products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

The 2007 results press and conference call will contain forward-looking statements, within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including those discussed in the release and others that can be found in the Risk Factors section of Antares Annual Report on Form 10-K for the year ended December 31, 2006 and in Antares periodic reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Antares is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements contained as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Contacts:

Antares Pharma, Inc.
Stephanie M. Baldwin
Senior Manager, Investor Relations
609-359-3032
sbaldwin@antarespharma.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here